Osimertinib as adjuvant therapy in patients (pts) with stage IB-IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA

被引：0
|
作者：
Grohe, C. [1 ]
Herbst, R. S. [2 ,3 ]
Tsuboi, M. [4 ]
John, T. [5 ]
Majem, M. [6 ]
Goldman, J. W. [7 ]
Kim, S. -W. [8 ]
Marmol, D. [9 ]
Rukazenkov, Y. [10 ]
Wu, Y. -L. [11 ]
Engel-Riedel, W. [12 ]
机构：
[1] Evangel Lungenklin Berlin Buch, Klin Pneumol, Berlin, Germany
[2] Yale Sch Med, Med Oncol, New Haven, CT USA
[3] Yale Canc Ctr, New Haven, CT USA
[4] Natl Canc Ctr Hosp East, Dept Thorac Surg & Oncol, Chiba, Japan
[5] Austin Hlth, Dept Med Oncol, Heidelberg, Vic, Australia
[6] Hosp Santa Creu & Sant Pau, Dept Med Oncol, Barcelona, Spain
[7] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[8] Asan Med Ctr, Dept Oncol, Seoul, South Korea
[9] AstraZeneca, Late Oncol Stat, Cambridge, England
[10] AstraZeneca, Oncol Res & Dev, Cambridge, England
[11] South China Univ Technol, Guangdong Lung Canc Inst, Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci,Sch Med, Guangzhou, Peoples R China
[12] Klinikum Stadt Koln gGmbH, Cologne, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2020年 / 43卷 / SUPPL 4期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
166
引用
收藏
页码：138 / 138
页数：1
相关论文
共 50 条
  • [31] A randomized, double-blind phase 3 trial of adjuvant erlotinib (E) versus placebo (P) following complete tumor resection with or without adjuvant chemotherapy in patients (pts) with stage IB-IIIA EGFR positive (IHC/FISH) non-small cell lung cancer (NSCLC): RADIANT results.
    Kelly, Karen
    Altorki, Nasser K.
    Eberhardt, Wilfried Ernst Erich
    O'Brien, Mary E. R.
    Spigel, David R.
    Crino, Lucio
    Tsai, Chun-Ming
    Kim, Joo-Hang
    Cho, Eun Kyung
    Szczesna, Aleksandra
    Burghuber, Otto
    Hoffman, Philip C.
    Keshavjee, Shaf
    Orlov, Sergey
    Serwatowski, Piotr
    Wang, Jiuzhou
    Foley, Margaret A.
    Horan, Julie D.
    Park, Jung Wook
    Shepherd, Frances A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [32] Natural history of curatively resected stage IB-IIIA EGFR mutation (+) NSCLC: Clinicopathologic and molecular prognostic factors (ROOT-EGFR-ADJ).
    Jung, Hyun Ae
    Jeon, Yeong Jeong
    Kim, Jhingook
    Park, Sehhoon
    Sun, Jong-Mu
    Lee, Se-Hoon
    Ahn, Jin Seok
    Ahn, Myung-Ju
    Park, Keunchil
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [33] HRQoL with Adjuvant Aumolertinib in Patients with Resected Stage IB-IIIA EGFR Mutant Non Small Cell Lung Cancer
    Hu, W.
    Mao, Z.
    Cheng, N.
    Huang, J.
    Tang, Z.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S563 - S564
  • [34] Phase IV trial of afatinib followed by osimertinib versus osimertinib alone as first-line treatment in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) NSCLC
    Wehler, T.
    Wehler, B.
    Atmaca-Dirik, H.
    Schulz, C.
    Grohe, C.
    Topsch, J.
    Ehrlich, A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S800 - S801
  • [35] Sequential Afatinib-Osimertinib Therapy in EGFR Mutation-Positive (EGFRm plus ) NSCLC: Analysis of Time on Treatment and OS
    Park, K.
    Tan, E.
    O'Byrne, K.
    Zhang, L.
    Boyer, M.
    Mok, T.
    Hirsh, V.
    Yang, J. C.
    Schuler, M.
    Yamamoto, N.
    Sequist, L.
    Wu, Y.
    Zhou, C.
    Ehrnrooth, E.
    Marten, A.
    Tang, W.
    Paz-Ares, L.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2215 - S2216
  • [36] Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer
    Herbst, Roy S.
    John, Thomas
    Grohe, Christian
    Goldman, Jonathan W.
    Kato, Terufumi
    Laktionov, Konstantin
    Bonanno, Laura
    Tiseo, Marcello
    Majem, Margarita
    Domine, Manuel
    Ahn, Myung-Ju
    Kowalski, Dariusz M.
    Perol, Maurice
    Sriuranpong, Virote
    Ozguroglu, Mustafa
    Bhetariya, Preetida
    Markovets, Aleksandra
    Rukazenkov, Yuri
    Muldoon, Caitlin
    Robichaux, Jacqulyne
    Hartmaier, Ryan
    Tsuboi, Masahiro
    Wu, Yi-Long
    NATURE MEDICINE, 2025,
  • [37] Rational application of EGFR-TKI adjuvant therapy in patients with completely resected stage IB-IIIA EGFR-mutant NSCLC: a systematic review and meta-analysis of 11 randomized controlled trials
    Shu-Ling Zhang
    Xiao-Fang Yi
    Le-Tian Huang
    Li Sun
    Jie-Tao Ma
    Cheng-Bo Han
    BMC Cancer, 23
  • [38] Rational application of EGFR-TKI adjuvant therapy in patients with completely resected stage IB-IIIA EGFR-mutant NSCLC: a systematic review and meta-analysis of 11 randomized controlled trials
    Zhang, Shu-Ling
    Yi, Xiao-Fang
    Huang, Le-Tian
    Sun, Li
    Ma, Jie-Tao
    Han, Cheng-Bo
    BMC CANCER, 2023, 23 (01)
  • [39] Osimertinib Maintenance After Definitive Chemoradiation in Patients with Unresectable EGFRm-Positive Stage III NSCLC (LAURA)
    Shun, L.
    Nash, T.
    Saggese, M.
    Mann, H.
    Ramalingam, S.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S497 - S497
  • [40] Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial (vol 41, pg 3877, 2023)
    不详
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (22) : 3877 - 3877
12345